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Abstract
Background Anal fissure (AF) is a common cause of anal
pain with a tendency not to heal spontaneously because of
ischemia of the anoderm caused by sphincter spasm. Lat-
eral internal sphincterotomy, while very effective, can
cause fecal incontinence and chemical sphincterotomy by
application of cream may have discouraging side effects
and/or low efficacy. The aim of this prospective multi-
center study was to evaluate the safety and effectiveness of
a new medical treatment based on Emulgel cream, with
emollient, soothing and protective agents, on AF healing.
Methods Consecutive patients with AF treated in nine
coloproctology units during 6 months entered the study on
topical treatment with Levorag Emulgel (THD S.p.A
Correggio (RE), Italy). Before treatment, they had a
proctologic examination and pain was measured using a
visual analog scale. THD Levorag Emulgel was applied
every 12 h for 40 days. Monitoring was scheduled at 10, 20
and 40 days. At time 0 and at the end of treatment, patients
underwent anorectal manometry, if possible.
Results Two hundred eighty-four AF patients were re-
cruited (171 acute fissures). Complete healing was
achieved in 47.9 % of the cases, an improvement in 31.0 %
(global efficacy 78.9 %). In patients with acute fissure, the
rate of efficacy was 89.4 % (complete healing: 64.3 %,
improvement: 25.1 %), in those with chronic fissure the
rate of efficacy was 62.8 % (complete healing: 23 %, im-
provement: 39.8 %), p\ 0.001. Pain and resting anal
pressure decreased significantly after treatment.
Conclusions Treatment with THD Levorag Emulgel
proved to be effective for the reepithelization of AF and the
reduction of pain in the short term in about 80 % of
patients.
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Introduction
Anal fissure (AF) is one of the most common anorectal
disorders, and, in Italy, the second most common problem,
after hemorrhoids, that brings patients to the proctologist’s
office [1]; AF is responsible for intense and prolonged anal
pain, often fails to respond to analgesic treatment with
consequent deterioration of the patient’s quality of life
[2, 3].
AF is characterized by ‘‘a linear ulcer of the anoderm,
distal to the dentate line’’ [4], is usually caused by minor
anal trauma at defecation and accounts for about 40 % of
the annual visits to a coloproctology unit according to a
recent annual report of the Italian Society of Colorectal
Surgery [1].
Despite significant progress made both in understanding
the etiology and pathogenesis of AF, and in developing
treatments based on internal sphincter relaxant agents [5],
there is still debate about what constitutes optimal treat-
ment is. In fact, AF treatment is one of the issues most
frequently studied and documented in the literature, which
is an indication of the clinical relevance of the problem
with and the awareness that the available treatment options
are still unsatisfactory.
The topical myorelaxant creams on the market were
shown to have limited advantages when compared with
placebo in randomized controlled trial [6, 7] and sig-
nificantly lower efficacy compared to lateral internal
sphincterotomy (LIS) [8], while the option of using bo-
tulinum toxin A injection is being abandoned [9, 10].
Furthermore, most of the myorelaxant creams available
(containing nitric oxide donors) have some unpleasant side
effects like headache, migraine and pruritus ani [7, 11],
which affect patients’ compliance, while other myorelax-
ants with few side effects (calcium channel blockers) are
not available in our country. On the other hand, LIS, which
is necessary in about one-third of AF patients [1] can
rapidly relieve symptoms, but the risk of early or late fecal
incontinence [12], even if low, prevents its application as a
first line therapy.
The availability of new effective and well-accepted
topical treatment, without side effects, is therefore eagerly
awaited.
The aim of our prospective multicenter observational
study was to evaluate the safety and efficacy of a new
topical cream, Levorag Emulgel (THD, SpA, Correggio,
(RE), Italy), in reducing pain and in the reepithelization of
AF.
Materials and methods
All consecutive patients with acute or chronic anal fissure
examined and treated in nine coloproctology units in
Southern Italy between June 2013 and January 2014, who
gave their informed consent to the study, entered this
prospective observational trial which qualified for ‘‘ex-
empt’’ on institutional review board because it was part of
the routine internal audit of the colorectal units involved in
the study.
Inclusion criteria were primary AF, acute or chronic
disease, and age range between 18 and 65 years. Acute
fissure was defined as a recent (within 1 month) ulceration
of the anoderm without the typical signs of a chronic fis-
sure (sentinel tag, induration of the lateral margins of the
fissure, eventual exposure of the internal anal sphincter)
[6]. Patients already under treatment with other topical
creams (containing nitric oxide donors, or calcium channel
blockers), as well as those with constipation requiring
prolonged straining or manual maneuvers during evacua-
tion, fecal incontinence, neoplasms, human immunodefi-
ciency virus infection, insulin dependent diabetes mellitus,
abscess and anal fistula, Crohn’s disease, advanced liver
disease, and pregnancy were excluded from the study.
The treatment included a topical application every 12 h
of THD Levorag Emulgel for 40 days. THD Levorag
Emulgel is a gel cream in 3.5-ml single-dose tubes con-
taining a mixture of substances with lubricating, film-
forming, emollient, soothing and protective properties
(Table 1). In particular, the lubricating agents were in-
cluded to create a film on the AF thus facilitating stool
expulsion and favoring pain reduction. Hydrolyzed hibis-
cus esculentus extract was added to improve the elasticity
of the tissues which, in combination with the expected
decrease of anal pain, according to the manufacturer’s in-
structions should lower the resting anal pressure, improv-
ing the microperfusion of the anoderm. Finally, the sodium
carboxymethyl beta-glucan component was added to favor
the reepithelization process.
The patients were invited to apply the creame with the
tip of the finger instead of inserting the anal cannula in-
cluded in the package because the use of the applicator
Table 1 Active components of THD Levorag Emulgel
Active components of THD Levorag Emulgel
Hibiscus esculentus extract
Carboxymethyl beta-glucan
Dimethicone, glycerine, prunus amygdalus dulcis oil, borago
officinalis seed oil
Malva sylvestris extract, calendula officinalis extract, glycyrrhiza
glabra extract
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(4.5 cm long) will deliver the gel to the rectum instead of
the anal canal. The patients were also invited to take oral
laxatives in order to reduce the hardness of the stools and
facilitate evacuation, and to clean their anus with disin-
fecting chlorhexidine-based solutions (Fisian, VAL-
DERMA srl, Terranuova Bracciolini, Italy). The use of oral
painkillers was allowed and recorded.
Clinical evaluation of patients was scheduled at time 0,
before starting the treatment, and at days 10, 20 and 40.
Baseline evaluation included a proctologic exam to deter-
mine the diagnosis and the type of fissure, and recording
the amount of anal pain, using a visual analog scale (VAS),
and other concomitant anal symptoms. Anal manometry to
document the anal resting pressure before and after treat-
ment was carried out in two of the units involved in the
study.
On day ten of treatment, the patients were interviewed
by phone to evaluate the level of pain and those without
any improvement or with further deterioration of symp-
toms were dropped from the study.
On day 20 of treatment, the patients underwent a proc-
tologic examination and pain was assessed with a VAS.
The degree of reepithelization of the fissure was scored as
follows: 0: deep fissure still present; 1: superficial fissure;
2: partial reepithelization or 3: complete healing and
reepithelization. Those without any improvement in reep-
ithelization or pain score were dropped from the study.
On day 40, the remaining patients underwent their last
evaluation including a proctologic examination, anal pain
score, and, if possible, anal manometry.
The results were divided according to outcome (suc-
cessful treatment and failure). Successful treatment was
defined as complete fissure healing or partial fissure reep-
ithelization associated with at least 50 % reduction of the
pain score after completing the scheduled 40 days of
treatment.
Sample size calculation
Sample size calculation were carried out by the website
http://www.raosoft.com/samplesize.html.
Assuming the VAS score would be reduced to 50 % of
the initial value, with an alpha error of 5 % and a beta error
of 10 %, and considering a possible dropout rate of 5 %, a
total of 281 patients were required to get statistical sig-
nificance with a 90 % confidence interval and a power of
the study of 90 %.
Statistical analysis
All data were prospectively entered into an excel database
by each of the participating centers and analyzed by the
coordinating center. Qualitative data were expressed using
the Wilcoxon rank sum test for paired data, while median
anal manometry data and pain scores were analyzed with
the Chi-square test. The ANOVA for repeated measures
was performed to evaluate the changes of pain scores over
time. A p value \0.05 was considered statistically
significant.
Results
Overall, 284 patients (130 males, mean age 44 ± 15 years)
were recruited in the nine colorectal units. One hundred
twenty-one of them had chronic AF, and 171 had acute AF.
The site of the fissure was posterior in 212 cases (74.7 %),
anterior in 58 (20.4 %) and anterior and posterior in 14
(4.9 %). The median anal pain score at baseline was 8 on a
0–10 VAS (10 = worst possible pain), while anal mano-
metry revealed high resting pressure (median 95 mmHg) in
all the 50 patients examined. A similar baseline average
pain score was observed in patients with acute or chronic
AF (8 vs 7.7 respectively, p = 0.8).
At day 10 of treatment (T1), six patients interviewed by
phone (1 with acute fissure) were excluded from the study
because of no pain relief. One more patient (with acute
fissure) was lost to follow-up.
At day 20 (T2) after clinical examination, another pa-
tient (with acute fissure) was lost to follow-up and 11 pa-
tients (four with acute fissure) were excluded from the
study (because of unaltered persisting pain.
At day 40, a total of 265 patients were available for final
evaluation, 164 with acute fissure and 101 with chronic
fissure. Overall, complete healing was achieved in 47.9 %
of the cases, and an improvement in 31 % (global efficacy
of 78.9 %). In patients with acute fissure, the rate of effi-
cacy was 89.4 % (complete healing: 64.3 %, improvement:
25.1 %), while in those with chronic fissure, it was 62.8 %
(complete healing: 23 %, improvement: 39.8 %)
(p\ 0.005) (Fig. 1).
The resting anal pressure in the 50 patients who un-
derwent anal manometry decreased significantly after
treatment, from a median of 95 mmHg at baseline to
60 mmHg (p\ 0.005), corresponding to a 40 % reduction
(Fig. 2).
The analysis of the VAS score for pain in the group of
patients who completed the study showed a progressive and
constant lessening of pain and a reduction of 81 % at the
end of the treatment (p\ 0.001), but without a significant
difference between the acute and chronic AF (Fig. 3).
No difference in the healing rate was observed accord-
ing to the sex of the patients (p = 0.58) or the site of the
fissure, (p = 0.77) while, as expected, acute fissure were
more likely to heal than chronic fissures (89.4 and 62.8 %,
respectively, p\ 0.001) (Fig. 4).
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Minor adverse effects consisting of soiling and an un-
pleasant smell due to the cream were reported by 6 % of
the patients but in no cases led to changes in the adherence
to the scheduled treatment.
Eighty-eight patients, who improved but did not have
complete fissure healing at the end of the study period,
spontaneously prolonged the treatment with THD Levor-
ag Emulgel out of the protocol for further 20 days.
Thirteen of them (14.8 %) finally achieved complete
healing. Lateral internal sphincterotomy was performed
on 72 % of the patients who failed with conservative
treatment (data available only from three of the nine
centers).
Discussion
After the pathogenic mechanisms underlying the tendency
of AF not to heal spontaneously were clearly described by
Schouten and co-workers [13] and by Lund and co-workers
[14], treatment of AF with chemical sphincterotomy using
myorelaxant creams, and thus avoiding the risk of iatro-
genic anal incontinence, has become a major goal in
proctology. A recent Cochrane review [7] on this topic
concluded that no medical treatment could claim the effi-
cacy of surgical sphincterotomy when compared in
prospective randomized controlled trial and that, among
the medical treatment examined, only glyceryl trinitrate
Fig. 1 Flow chart showing the
outcome of the trial
Fig. 2 a Anal manometry
before and after 40 days of
treatment in patients with acute
anal fissures. b Anal manometry
before and after 40 days of
treatment in patients with
chronic anal fissures
290 Tech Coloproctol (2015) 19:287–292
123
ointment showed a marginally significant advantage com-
pared to placebo. Furthermore, a significant proportion of
these patients drop out of treatment because of headache,
and up to 50 % of them experience symptom recurrence in
the long term [7].
The need of further medical solutions to this painful
disease has therefore been eagerly awaited.
Although the lack of a control group is an important
limitation to our study, this large multicenter prospective
trial shows that topical treatment with THD Levorag
Emulgel can help about 89 % of patients with acute AF and
63 % of those with chronic AF, leading to complete fissure
healing in 64.3 and 23 % of acute and chronic AF, re-
spectively, and allowing a significant reduction of anal pain
after the first week of treatment and in the following weeks.
Moreover, a further percentage (about 15 %) of fissures not
yet healed within the study period completed the healing
process in the next 20 days of treatment. The adoption of
strict criteria for defining fissure healing, used for the first
time in this study, made the results of treatment even more
reliable. Another limitation of this study is that it was ex-
plicitly designed to evaluate the ability to control the anal
pain which is the major patient complaint, and therefore,
the sample size was calculated based on this instead of the
healing rate.
The association of substances promoting tissue healing
contained in THD Levorag Emulgel resulted in a good
patient compliance and no side effects, while the reduction
of the anal resting tone was documented in a significant
subgroup of these patients.
Conclusions
THD Levorag Emulgel was proven to be an effective and
well-tolerated topical treatment for both acute and chronic
AF in the short term, constituting one more arrow to the
bow of proctologists in treating this painful disease, and
compares well with the other conservative medical treat-
ments even if the long-term outcome remains to be
evaluated.
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